Taking also into account that, besides CK2, it inhibits PIM-1 (a very important and innovative target in cancer therapy [29–31]), CLK2, and, with lower efficacy, also DYRK1A [12], we believe that TDB displays good features to be considered for future clinical experimentation. This evidence concerns the gene DYRK1A and cancer.